990x120-1

Event Overview

From hitting new therapeutic targets to developing new diagnostic methods, aptamers are bringing much-needed solutions to drug and diagnostic development. With existing technologies covering less than 30 percent of the human proteome, there is an unmet need for biomolecular recognition in the drug target space. Aptamers are single-stranded oligonucleotides that bind a wide range of proteins with high affinity and specificity, similar to antibodies. Because of their versatility, scientists are developing aptamers to perform a variety of functions, such as binding to drug targets and acting as point-of-care and wearable biosensors.

In this roundtable event brought to you by Aptamer Group, experts from academia, industry and healthcare will discuss the need for aptamers in drug and diagnostic development, highlighting the pros and cons of working with this technology and its approach to the market across therapeutic, diagnostic and bioprocessing sectors.
Thursday, June 23, 2022

11:00 AM Eastern Time (8:00 AM PT)

This webinar will also be available on-demand.



Meet the panel

Koonin.png
Moderator
Sejal Davla, PhD
Assistant Science Editor
The Scientist
Koonin.png
Netz Arroyo, PhD
Assistant Professor
Pharmacology and Molecular Sciences
Joint Faculty, Chemical and Biomolecular Engineering
Member, Institute for Nanobiotechnology
Johns Hopkins University School of Medicine
Koonin.png
Jonathan Royce, MS
Chief Executive Officer
Bio-Works Technologies
Koonin.png
Daniel Wiseman, MD
Oglesby Leukaemia Research Group
Division of Cancer Sciences
Department of Haematology
The Christie NHS Foundation Trust
The University of Manchester
Koonin.png
David Bunka, PhD
Chief Technological Officer
Aptamer Group
Sponsored by

thermo

Register

You must have Javascript and Cookies enabled to access this webcast.

Information you provide will be shared with the sponsors for this content. The Scientist or its sponsors may contact you to offer you content or products based on your interest in this topic. You may opt-out at any time.